PARIS – Robocath SAS, of Rouen, France, has secured a new $43 million funding round to boost roll-out of its R-One robotic system for treating vascular disease. This series C funding was led by Hong Kong-based Microport Scientific Corp.
BEIJING – Three-year-old Asia-focused startup Everest Medicines Ltd. closed one of the biggest financing rounds in China’s health care market this year, adding $310 million to its war chest. The firm is aiming to advance its late-stage assets in-licensed from global partners to the China market soon.
LONDON – Exscientia Ltd. has closed a $60 million series C funding, attracting Novo Holdings as new investor to lead the round, which will enable the artificial intelligence (AI) specialist to progress its first in-house program to the clinic before the end of 2020.
Avectas Ltd., of Dublin, brought in a $20 million series C financing, ratcheting the total equity investment in the company to $40 million. Privately held Avectas, formed in 2012 as a spin-out from Ireland’s Maynooth University, said it plans to accelerate the clinical translation and commercial scale-up of its cell engineering technology and expand its staffing in Ireland.
HONG KONG – Chinese biopharmaceutical company Abbisko Therapeutics Co. Ltd., of Shanghai, defied turbulent stock markets amid the COVID-19 pandemic to snag $70 million in its latest round of financing.
HONG KONG – Chinese biopharmaceutical company Abbisko Therapeutics Co. Ltd., of Shanghai, defied turbulent stock markets amid the COVID-19 pandemic to snag $70 million in its latest round of financing.
Keros Therapeutics Inc. CEO Jasbir Seehra told BioWorld that he plans to use at his new company lessons learned as co-founder of Acceleron Pharma Inc., where work with receptors in the TGF-beta superfamily “taught me the potential of the biology and those molecules, but also the limitations” with regard to safety that need to be surmounted.
San Francisco-based startup Element Science Inc. has raised a massive financing in support of the first product that is part of its next-generation digital wearable platform. The $145.6 million series C financing is slated to support the company through clinical trial completion and commercial launch of its Jewel Patch Wearable Cardioverter Defibrillator.
DUBLIN – Neotx Therapeutics Ltd. raised $45 million in a series C round to continue clinical development of an immuno-oncology agent that already has a long clinical history behind it. Its lead molecule, naptumomab estafenatox, is a fusion protein comprising an antibody fragment that recognizes the oncofetal antigen 5T4 and a bacterial “super-antigen” comprising a modified version of the Staphylococcal enterotoxin A.
Alx Oncology Inc. pulled down a $105 million series C equity financing to support the expansion into phase II trials with ALX-148, described as a next-generation CD47 myeloid checkpoint inhibitor, paired with other cancer therapeutics. ALX-148 uses a “dead” Fc domain that does not bind to macrophages, thus reducing cytopenia and other toxicities associated with the class.
RSS
